{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:50:19Z","timestamp":1793353819753,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dld.2026.07.013","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:47:43Z","timestamp":1785556063000},"page":"1339-1348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patterns of progression and efficacy of immune checkpoint inhibitors in unresectable, recurrent, or metastatic cholangiocarcinoma: A real-world study"],"prefix":"10.1016","volume":"58","author":[{"given":"Yupeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.07.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108489","article-title":"Biliary tract cancer","volume":"51","author":"S\u00f8reide","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.07.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0004","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.07.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100378","article-title":"How I treat biliary tract cancer","volume":"7","author":"Lamarca","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2026.07.013_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.dld.2026.07.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100503","article-title":"Advances in the systemic treatment of therapeutic approaches in biliary tract cancer","volume":"7","author":"Mirallas","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2026.07.013_bib0008","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhepr.2019.06.003","article-title":"Immunobiology of cholangiocarcinoma","volume":"1","author":"Loeuillard","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.07.013_bib0009","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10238-024-01460-7","article-title":"Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.dld.2026.07.013_bib0010","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.dld.2026.07.013_bib0011","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.07.013_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.724722","article-title":"Patterns of failure in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Chai","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0013","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1186\/s12885-024-12888-1","article-title":"Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study","volume":"24","author":"Deng","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2026.07.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0015","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0016","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxf Engl: 1990)"},{"key":"10.1016\/j.dld.2026.07.013_bib0018","article-title":"Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.dld.2026.07.013_bib0019","doi-asserted-by":"crossref","first-page":"12482","DOI":"10.1002\/cam4.5959","article-title":"Metastatic sites and lesion numbers cooperated to predict efficacy of PD-1 inhibitor-based combination therapy for patients with metastatic colorectal cancer","volume":"12","author":"Jiang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.dld.2026.07.013_bib0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.hpb.2018.09.006","article-title":"CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts","volume":"21","author":"Laurent","year":"2019","journal-title":"HPB"},{"key":"10.1016\/j.dld.2026.07.013_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188409","article-title":"Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter","volume":"1875","author":"Luo","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.dld.2026.07.013_bib0022","article-title":"CA19-9-related macrophage polarization drives poor prognosis in HCC after immune checkpoint inhibitor treatment","volume":"14","author":"Du","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.dld.2026.07.013_bib0024","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.3748\/wjg.v22.i45.9933","article-title":"Reprogramming of glucose metabolism in hepatocellular carcinoma: progress and prospects","volume":"22","author":"Shang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2026.07.013_bib0025","article-title":"Prognostic role of inflammatory and tumor biomarkers in hilar cholangiocarcinoma patients receiving postoperative adjuvant therapy","volume":"15","author":"Zeng","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0026","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.34854","article-title":"The association of carbohydrate antigen 19-9 response with radiologic response and survival in intrahepatic cholangiocarcinoma: a prospective cohort study","volume":"129","author":"Cai","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2026.07.013_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1651769","article-title":"Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies","volume":"16","author":"Xue","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.dld.2026.07.013_bib0028","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/cells12060846","article-title":"Heterogeneity of cholangiocarcinoma immune biology","volume":"12","author":"Vita","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.dld.2026.07.013_bib0029","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/cells12060862","article-title":"Revealing the heterogeneity of the tumor ecosystem of cholangiocarcinoma through single-cell transcriptomics","volume":"12","author":"Golino","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.dld.2026.07.013_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat, Med"},{"key":"10.1016\/j.dld.2026.07.013_bib0031","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41420-024-02079-z","article-title":"Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma","volume":"10","author":"Sun","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.dld.2026.07.013_bib0032","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2478\/raon-2023-0059","article-title":"Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"57","author":"Zhang","year":"2023","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.dld.2026.07.013_bib0033","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat, Immunol"},{"key":"10.1016\/j.dld.2026.07.013_bib0034","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/s43018-025-01018-w","article-title":"Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.dld.2026.07.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.dld.2026.07.013_bib0036","first-page":"1","article-title":"Hepatic artery infusion chemotherapy combined with lenvatinib and PD-1 inhibitors in the treatment of intermediate and advanced unresectable hepatocellular carcinoma","volume":"30","author":"Jiang","year":"2025","journal-title":"Oncol Lett"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582600811X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582600811X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:20:02Z","timestamp":1790335202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582600811X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S159086582600811X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.07.013","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of progression and efficacy of immune checkpoint inhibitors in unresectable, recurrent, or metastatic cholangiocarcinoma: A real-world study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}